HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

6th Edition of World Congress on Infectious Diseases

June 24-26, 2024 | Paris, France

June 24 -26, 2024 | Paris, France
Infection 2023

Diana Gonzaga Ramos

Speaker at World Congress on Infectious Diseases 2023 - Diana Gonzaga Ramos
Research Institute for Tropical Medicine, Philippines
Title : Determinants of early virologic failure among hiv patients on first-line anti-retroviral therapy


The initiation of anti-retroviral therapy (ART) effectively restores immune function and reduces HIV-related morbidity and mortality. However, virologic failure while on ART may lead to increased morbidity and compromised quality of life. The aim of this study was to determine the prevalence and determinants of early virologic failure (VF) among HIV patients on first-line ART enrolled at the Research Institute for Tropical Medicine, Philippines.
Patients and methods:
A retrospective cohort study was conducted involving treatment-naïve HIV patients who were started on ART during the period of January 2004 – December 2018. Early virologic failure was defined as HIV-1 viral load of > 1,000 copies / ml of plasma blood taken within 6 months or more of first-line ART. Data regarding patients’ sociodemographic profile, baseline clinical characteristics, and treatment-related information were collected through database review. Data were analyzed using STATA 15.0. Descriptive statistics, cross-tabulations, and univariate and multivariate logistic regressions were utilized. P<0.05 was used to determine clinical significance.
Among the 1900 subjects included in this study, 1839 were males (96.79 %). The mean age at ART initiation was 30.36 years (SD 6.89) with a baseline CD4 count of 232.30 cells / mm3 (SD 204.19). The average time from ART initiation to
the first VL determination was 4 years (SD 28.62). A total of 72 (3.79 %) subjects were found to have virologic failure. Younger age (15-20 years), baseline CD4 count <50 cells/mm3, and TB co-infection were found to be significant predictors of early virologic failure in the univariate logistic regression analysis. Multivariate logistic regression showed that patients with age 15-20 years were 5-6 times more likely to have VF (1 / adjusted OR 0.18 = 5.55, p-value of 0.024) while patients with baseline CD4 count of <50 cells/mm3 were 3 times (1 / adjusted OR 0.35 = 2.86, p-value <0.01) more likely to have virologic failure.
The prevalence of early virologic failure among HIV patients on first-line anti-retroviral therapy is 3.79 %, relatively lower compared to other published data. Early virologic failure was most likely to occur among patients 15-20 years old and/or those with baseline CD4 count below 50 cells/mm3. Presence of these factors should be used as a marker for intensified adherence counselling especially in the absence of reliable or readily available viral load monitoring.
HIV, early virologic failure, risk factor, anti-retroviral drugs, first-line anti-retroviral therapy

Audience take away:
• To the knowledge of the principal investigator, this study provides the first local data for early HIV virologic failure in the Philippines.
• This study highlights the need for intensified adherence counselling in the presence of risk factors for early virologic failure.
• This study also emphasized special attention to early tuberculosis diagnosis during ART enrollment being a possible risk factor in early virologic failure which can also be used in future studies.


Dr. Diana Gonzaga Ramos is a practicing internist and infectious disease specialist in Las Piñas City and Muntinlupa City, Philippines. She completed her Medical Degree at Pamantasan ng Lungsod ng Maynila in 2007. She finished her residency training in Internal Medicine at Ospital ng Makati in 2013 and completed her subspecialty training in Infectious Diseases at Research Institute for Tropical Medicine in 2019. She is also a Fellow of the Philippine College of Physicians and a Diplomate of the Philippine Society for Microbiology and Infectious Diseases.